Promoted Content Promoted Content

X

Find FDA Investigational New Drug (IND) Submissions for Gastroenterology

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Country filter
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): GT-2108

            Therapeutic Area: Gastroenterology Product Name: GT-2108

            Highest Development Status: IND Enabling Product Type: Small molecule

            Partner/Sponsor/Collaborator: Amplitude Ventures

            Deal Size: $1.2 million Upfront Cash: Undisclosed

            Deal Type: Financing June 30, 2021

            Details:

            Giiant Pharma already initiated its IND-enabling preclinical program with its lead candidate, GT-2108, for the treatment of moderate-to-severe ulcerative colitis. This additional financing will support the development of GT-2108 up to clinical Phase 1b completion.